Evoke Pharma's 15-min chart shows a KDJ Death Cross and Bearish Marubozu.

According to Evoke Pharma's 15-minute chart, a KDJ Death Cross and a Bearish Marubozu were triggered on August 28th at 4:00 PM. This indicates a shift in momentum towards a downward trend, with potential for further decreases in stock price. Sellers currently dominate the market, and bearish momentum is likely to persist.

Evoke Pharma, Inc., a specialty pharmaceutical company focused on gastrointestinal (GI) diseases, has announced significant strategic partnerships aimed at expanding access to its flagship treatment, GIMOTI (metoclopramide) nasal spray. The company, in collaboration with Eversana, a leading provider of global commercial services to the life sciences industry, has entered into agreements with Omnicell and Brentwood Pharmacy to enhance patient access to GIMOTI.

Omnicell, a leader in medication management and fulfillment, will manage the collection of specialty pharmacies that specialize in GI products and are affiliated with large gastrointestinal physician organizations. This partnership is expected to almost double the number of specialty pharmacies available to access GIMOTI, thereby significantly improving patient access to the only FDA-approved nasal spray for adults with acute and recurrent diabetic gastroparesis.

The addition of Omnicell as a pharmacy manager aligns with Evoke's strategy to improve patient access by aligning with the specialty pharmacies that GI physicians trust and use daily. Chris Quesenberry, Chief Commercial Officer at Evoke Pharma, noted, "Large GI practices are structured for scale and efficiency, and many have long-standing relationships with preferred specialty pharmacies. Omnicell is an organization that understands the complexities of specialty care and offers turnkey solutions intended to optimize provider and patient experience."

In a separate agreement, Evoke has accessed Brentwood Pharmacy via a partnership agreement facilitated by Eversana. Brentwood Pharmacy is the specialty pharmacy affiliated with OneGI, a large gastroenterology network located in Tennessee, Kentucky, Ohio, Mississippi, and surrounding states. OneGI manages approximately 200 gastroenterologists and specialized physician assistants located at over 30 offices. This expansion further enables rapid delivery of GIMOTI and expands access to additional insurance plans for patients.

GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The gastric delay caused by gastroparesis can compromise the absorption of orally administered medications, making GIMOTI a crucial treatment option. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.

Evoke Pharma is committed to improving patient access to GIMOTI through strategic partnerships and innovative commercial strategies. The company's focus on aligning with trusted specialty pharmacies and expanding access to GIMOTI is a direct reflection of its commitment to improving patient outcomes.

References

[1] Evoke Pharma and Eversana Expand GIMOTI Access to Gastro Health and Other Large GI Practices. Retrieved from [https://www.marketscreener.com/news/evoke-pharma-and-eversana-expand-gimoti-access-to-gastro-health-and-other-large-gi-practices-through-ce7c50dedf81f722](https://www.marketscreener.com/news/evoke-pharma-and-eversana-expand-gimoti-access-to-gastro-health-and-other-large-gi-practices-through-ce7c50dedf81f722)